Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 12;100(10):e24003.
doi: 10.1097/MD.0000000000024003.

Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study

Xia-Li Mao  1 , Ya-Ming Xi, Zi-Jian Li, Ming-Feng Jia, Ming Li, Li-Na Wang, Long Zhao, Hao Zhang
Affiliations

Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study

Xia-Li Mao et al. Medicine (Baltimore). .

Abstract

The aim of this study was to evaluate the ability of the red blood cell distribution width (RDW) to predict prognosis and treatment response in chronic myeloid leukemia (CML)-chronic phase (CP) patients treated with tyrosine kinase inhibitor (TKIs).We retrospectively enrolled 93 newly diagnosed CML-CP patients treated with TKIs from 2009 to 2018 at the First Hospital of Lanzhou University. Patients were divided into 2 groups using an RDW of 18.65% determined by receiver operating characteristic curve analysis. We analyzed the correlation of treatment responses and the RDW compared to common scoring systems, as well as the correlation of the RDW with disease outcome, including overall survival (OS) and progression-free survival (PFS), and demographic and laboratory factors affecting outcome. Univariate analysis and Cox regression analysis were used.The median age of patients was 40 years, and 51 patients (54.8%) were men. A high RDW could predict treatment response at 3 months (P = .03) and 6 months (P = .02). The RDW was significantly lower in patients who achieved molecular response by 3 months (P < .001) and complete cytogenetic response by 6 months (P = .001) than in those who did not respond. Patients with a high RDW (>18.65%, n = 35) had significantly worse 5-year OS (77.1% vs 96.6%; P = .008) and PFS (80.0% vs 98.3%; P = .002) than those with a low RDW (≤18.65%, n = 58). Multivariate analysis demonstrated that a high RDW was an adverse predictor of OS (P = .005, HR (hazard ratio) = 9.741) and PFS (P = .009, HR = 16.735).The RDW is a readily available prognostic marker of outcome in patients with CML-CP and can predict treatment response to TKIs. Further larger and prospective studies are required.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of the screening process of this study.
Figure 2
Figure 2
ROC analysis for determining the optimal cut-off value in predicting OS (A) and PFS (B) for RDW.
Figure 3
Figure 3
Baseline RDW value in patients with CML-CP were divided according to the clinical efficacy.(A) early molecular response by 3 months (3M-EMR), (B) complete cytogenetic response by 6 months(6M-CCyR), (C) major molecular response by 12 months (12M-MMR).
Figure 4
Figure 4
Kaplan-Meier curves for OS (A) and PFS (B) according to RDW.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA 2020;70:7–30. - PubMed
    1. Pan P, Wang L, Wang Y, et al. . Systematic review and meta-analysis of -new-generation tyrosine kinase inhibitors versus imatinib for newly diagnosed chronic myeloid leukemia. Acta Haematol 2019;12:1–3. - PubMed
    1. Balakumaran J, Birk T, Golemiec B, et al. . Evaluating the endometabolic and bone health effects of tyrosine kinase inhibitors in chronic myeloid leukaemia: a systematic review protocol. BMJ Open 2019;9:e030092. - PMC - PubMed
    1. Howlader N, Noone A, Krapcho M, et al. . SEER Cancer Statistics Review, 1975–2016. National Cancer Institute 2019. https://seer.cancer.gov/csr/1975_ 2016/ (accessed 3 February 2020).
    1. Deininger MW, Shah NP, Altman JK, et al. . Chronic myeloid leukemia, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020. https://www.nccn.org/professionals/physician gls/pdf/cml.pdf - PubMed

Substances